Age-Related Macular Degeneration

A biomarker panel of three serum metabolites associated with the onset, severity and progression of age-related macular degeneration may aid in earlier detection and monitoring of disease, according to researchers.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the next steps for the phase 3 SOL-1 and SOL-R studies.

CHICAGO — Decreasing vitamin A dimerization may be a promising treatment avenue for treating geographic atrophy, according to a speaker here.

Systemic and ocular comorbidities are common in the patient who presents for cataract surgery.

In this Healio Video Perspective from the Retina Society meeting, Mark R. Barakat, MD, discusses the 26-week interim analysis for Ixo-vec for the treatment of neovascular age-related macular degeneration.

Aviceda Therapeutics has completed enrollment of its phase 2b SIGLEC study, which will compare the safety and efficacy of AVD-104 vs. Izervay in patients with geographic atrophy secondary to age-related macular degeneration.

Healio spoke with Aleksandra Rachitskaya, MD, a vitreoretinal surgeon and associate professor of ophthalmology at Cleveland Clinic Cole Eye Institute, about mental health conditions in patients with age-related macular degeneration.

Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.

In this video, Barbara Blodi, MD, discusses long-term data on geographic atrophy growth rates in treatment-naive patients with age-related macular degeneration.

The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.